High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)